Welcome to our dedicated page for SAB Biotherapeutics SEC filings (Ticker: SABSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics filings document a clinical-stage biopharmaceutical issuer focused on SAB-142 and human immunoglobulin G therapies for autoimmune disease. Recent Form 8-K disclosures cover Regulation FD clinical presentations for the SAB-142 HUMAN trial, other clinical data announcements, and a manufacturing services agreement for clinical and commercial supply of SAB-142.
The company’s proxy materials describe annual meeting matters, director elections, board governance, stockholder voting procedures, and executive-compensation disclosures. Its SEC record also identifies capital-structure items including common stock and warrants exercisable for common stock, along with risk and forward-looking disclosure tied to clinical development, regulatory approval, manufacturing, and financing needs.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of SAB Biotherapeutics, Inc. common stock. The Master Fund directly holds 6,627,501 shares of common stock, representing 7.3% of the class based on 90,986,368 shares outstanding as of August 3, 2026.
Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member of Perceptive Advisors, may each be deemed to beneficially own these shares. All 6,627,501 shares are reported with shared voting and shared dispositive power; no reporting person has sole voting or sole dispositive power.
Caligan Partners LP and David Johnson filed an amended Schedule 13G reporting their beneficial ownership of common stock of SAB Biotherapeutics, Inc. Caligan, as investment manager to certain funds and accounts, and Johnson, as its managing partner, are the reporting persons.
They report beneficial ownership of 7,967,207 shares of SAB Biotherapeutics common stock, representing 8.8% of the class, based on 90,986,368 shares outstanding as of August 3, 2026. All reported shares are held with shared voting and dispositive power; neither reporting person has sole voting or sole dispositive power over these shares.
The filing notes that other persons (the underlying funds and accounts) may have rights to receive dividends or proceeds from the sale of these securities in accordance with the investment structure referenced in Item 2(a). David Johnson signs the report both in his capacity as managing partner of Caligan and in his individual capacity.
Commodore Capital and related filers report a significant ownership position in SAB Biotherapeutics, Inc. As of June 30, 2026, they may be deemed to beneficially own 8,948,170 shares of common stock, representing 9.9% of the class. This position includes 2,870,000 common shares, 5,946,400 shares issuable upon conversion of Series B Preferred Stock, and 131,770 shares issuable upon conversion of Series B Preferred Stock underlying Tranche 1 Warrants. Additional Tranche 1 and Tranche 2 Warrants are contractually limited by a 9.99% Beneficial Ownership Limitation, so those excluded securities are not counted in the reported stake.
SAB Biotherapeutics, Inc. received an amended Schedule 13G indicating that Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC may be deemed to beneficially own 22,637,108 shares of common stock and equivalents, while Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC may be deemed to beneficially own 2,286,301 shares.
These positions include existing common shares plus shares issuable upon conversion of Series B Preferred Stock and upon exercise of related Enrollment Warrants and Data Release Warrants that are exercisable or convertible within 60 days. Each reporting person reports beneficial ownership of 9.99% of the common stock class, with blocking provisions in the preferred stock and warrants that prevent conversions or exercises which would increase ownership above 9.99% of the issuer’s voting securities.
Woodline Partners LP filed an amended Schedule 13G reporting beneficial ownership of 5,455,355 shares of SAB Biotherapeutics, Inc. common stock, including shares issuable upon conversion of preferred stock underlying warrants. This represents 6.8% of the outstanding common stock.
The position consists of 1,180,355 common shares, plus 2,850,000 shares issuable from Series B Preferred Stock underlying Enrollment Warrants and 1,425,000 shares issuable from Series B Preferred Stock underlying Data Release Warrants, all held for Woodline Master Fund LP. The percentage is based on 76,464,094 common shares outstanding as of May 6, 2026. Woodline reports sole voting and dispositive power over the 5,455,355 shares, with the Woodline Fund entitled to dividends and sale proceeds.
Balyasny Asset Management and related entities reported significant ownership in SAB Biotherapeutics, Inc. common stock. Through Atlas Diversified Master Fund, Ltd. and Atlas Private Holdings (Cayman) Ltd., they beneficially own 7,225,439 shares, including 3,465,000 shares issuable upon exercise of 34,650 warrants.
This position represents approximately 9.45% of SAB Biotherapeutics’ 76,464,094 shares outstanding as of May 6, 2026. The warrants are subject to a Beneficial Ownership Limitation that blocks exercises which would result in ownership above 9.99% of outstanding shares.
Adage Capital Management, L.P. and related entities and individuals report beneficial ownership of 6,405,553 shares of SAB Biotherapeutics, Inc. common stock. This represents 8.38% of the company’s outstanding common stock, based on 76,464,094 shares outstanding as of May 6, 2026.
The reporting persons have shared voting and dispositive power over all 6,405,553 shares and no sole voting or dispositive power. The shares are held directly by Adage Capital Partners, L.P., with Adage Capital Management, L.P. as investment manager and Robert Atchinson and Phillip Gross reporting through their managing member roles in related entities.
RA Capital Management, L.P. and affiliated reporting persons report beneficial ownership of 9,609,852 shares of SAB Biotherapeutics, Inc. common stock, representing 9.9% of the class based on 90,986,368 shares outstanding as of August 3, 2026. This amendment reflects a change in ownership percentage due to an increase in SAB’s outstanding shares, not any new acquisitions or dispositions by the group.
The RA Capital Healthcare Fund directly holds 4,401,500 common shares, Series B preferred stock convertible into up to 12,738,500 common shares, preferred stock purchase warrants, and pre-funded warrants exercisable for up to 2,753,246 common shares. A Beneficial Ownership Blocker currently limits the fund and its affiliates from beneficially owning more than 9,609,852 common shares, with a default cap of 9.99%, adjustable up to 19.99% on 61 days’ notice.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing multi-specific human IgG therapies, reported higher operating spending and net losses for the quarter ended June 30, 2026 while strengthening its capital base. The company’s lead asset, SAB-142, is in a registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes.
Total operating expenses for Q2 2026 were $23,377 (in thousands), driven by research and development of $16,172 (in thousands) and general and administrative of $7,205 (in thousands). Net loss for the quarter was $22,491 (in thousands), and for the first six months of 2026 it was $41,360 (in thousands), or $0.62 basic and diluted loss per share.
As of June 30, 2026, the company held cash and cash equivalents of $8,267 (in thousands), short-term investments of $94,365 (in thousands), and long-term investments of $105,346 (in thousands), supporting total assets of $238,210 (in thousands) and stockholders’ equity of $214,785 (in thousands). A March 2026 public offering of common stock and pre-funded warrants generated net proceeds of approximately $88,697 (in thousands). Based on its current operating expense level, management states existing resources are expected to cover operating cash needs for at least twelve months following the report date.
SAB Biotherapeutics, Inc. filed a current report describing a new grant-funded clinical study of its lead candidate SAB-142 in type 1 diabetes. Breakthrough T1D has awarded a grant to support the PRISE‑hATG trial, led by Dr. Michael J. Haller at the University of Florida.
The PRISE‑hATG study will evaluate SAB‑142 in patients with Stage 3 type 1 diabetes who are between 100 days and two years from diagnosis, a group that typically falls outside earlier-stage trials. SAB BIO will co-fund the trial, which is designed to assess whether SAB‑142 can preserve C‑peptide and modulate immune responses. The study complements SAB BIO’s ongoing Phase 2b SAFEGUARD trial of SAB‑142 in newly diagnosed Stage 3 patients.